__NUXT_JSONP__("/drugs/Siltuximab", (function(a,b,c,d,e){return {data:[{drug:{slug:a,emaEpar:[{activeSubstance:c,conditionIndication:"Sylvant is indicated for the treatment of adult patients with multicentric Castlemanâ€™s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.",inn:c,marketingAuthorisationDate:"2014-05-22 00:00:00",marketingAuthorisationHolder:"EUSA Pharma (Netherlands) BV",medicineName:b,url:"https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fmedicines\u002Fhuman\u002FEPAR\u002Fsylvant"}],fdaDrugLabel:[{brand:b,indication:"1 INDICATIONS AND USAGE SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. SYLVANT is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. ( 1 ) Limitations of Use SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study. Limitations of Use SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.",manufacturer:"EUSA Pharma (UK) Ltd",splSetId:"8d663642-f52e-49c0-a023-2da083fdfc0b"}],id:a,nciThesaurus:{casRegistry:"541502-14-1",chebiId:d,chemicalFormula:d,definition:"A chimeric, human-murine, monoclonal antibody targeting the pro-inflammatory cytokine interleukin 6 (IL-6), with antitumor and anti-inflammatory activities. Upon intravenous administration of siltuximab, this agent targets and binds to IL-6. This inhibits the binding of IL-6 to the IL-6 receptor (IL-6R), which results in the blockade of the IL-6\u002FIL-6R-mediated signal transduction pathway. This inhibits cancer cell growth in tumors overexpressing IL-6.",fdaUniiCode:"T4H8FMA7IM",identifier:"C61084",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C163951"],synonyms:["Anti-IL-6 Chimeric Monoclonal Antibody","CNTO 328","CNTO-328","SILTUXIMAB",a,b,"anti-IL-6 chimeric monoclonal antibody","cCLB8"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FSiltuximab",extension:".json",createdAt:e,updatedAt:e}}],fetch:{},mutations:void 0}}("Siltuximab","Sylvant","siltuximab","","2021-10-30T13:41:20.073Z")));